Moderna’s stock soared more than double after revealing breakthrough results for a new mRNA melanoma vaccine, designed to work alongside Merck’s immunotherapy drug to prevent cancer recurrence post-surgery. This personalized treatment could drastically improve survival rates for thousands of U.S. melanoma patients annually, with researchers calling it a “landmark moment.” Though Moderna’s shares remain below their pandemic highs, the potential to transform early-stage melanoma care is enormous — and regulators are poised to review the data soon.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
